Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study
| Autor: | Henry R. Black, Georges Tannoury, Jennifer V. Linseman, Mahfouz El Shahawy, George L. Bakris, Robert J. Weiss, Brian L. Wiens, Richard Marple, Stuart L. Linas, Robert Roden, Michael A. Weber, Michael J. Gerber |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Endothelin Receptor Antagonists Male medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Adrenergic beta-Antagonists Drug Resistance Angiotensin-Converting Enzyme Inhibitors Placebo law.invention Randomized controlled trial Double-Blind Method law Internal Medicine medicine Humans Adverse effect Diuretics Antihypertensive Agents Aged Aged 80 and over Phenylpropionates Endothelin receptor antagonist business.industry Middle Aged Dose-ranging study Calcium Channel Blockers Original Papers Surgery Blood pressure Pyrimidines Anesthesia Hypertension Darusentan Drug Therapy Combination Female Diuretic Cardiology and Cardiovascular Medicine business Angiotensin II Type 1 Receptor Blockers |
| Zdroj: | J Clin Hypertens (Greenwich) |
| ISSN: | 1524-6175 |
| Popis: | In this phase 2, randomized, double-blind, placebo-controlled forced dose-titration study, 115 patients with resistant hypertension, receiving background therapy with >/=3 antihypertensive medications including a diuretic at full doses, were randomized 2:1 to increasing doses of darusentan (10, 50, 100, 150, and 300 mg), a selective endothelin receptor antagonist, or matching placebo once daily for 10 weeks. Darusentan treatment decreased mean systolic and diastolic blood pressure levels in a dose-dependent fashion compared with placebo; the largest reductions were observed at week 10 (300-mg dose) (systolic, -11.5+/-3.1 mm Hg [P=.015;] diastolic, -6.3+/-2.0 mm Hg [P=.002]). Darusentan (300 mg) also decreased mean 24-hour, daytime, and nighttime ambulatory blood pressures from baseline to week 10. Darusentan was generally well tolerated; mild to moderate edema and headache were the most common adverse events. This study demonstrates a clinical benefit from a new class of antihypertensive agent in patients classified as resistant by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|